These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18831925)

  • 1. Quantification of sirolimus and everolimus by immunoassay techniques: test specificity and cross-reactivity evaluation.
    Pieri M; Miraglia N; Gentile A; Polichetti G; Castiglia L; Federico S; Sabbatini M; Basile V; Tarantino G; Acampora A; Capone D
    Int J Immunopathol Pharmacol; 2008; 21(3):585-94. PubMed ID: 18831925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of everolimus in whole blood using the Abbott IMx sirolimus microparticle enzyme immunoassay.
    Bouzas L; Tutor JC
    Clin Biochem; 2007 Jan; 40(1-2):132-6. PubMed ID: 17011541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of blood sirolimus concentrations in liver and kidney transplant recipients using the Innofluor fluorescence polarization immunoassay: comparison with the microparticle enzyme immunoassay and high-performance liquid chromatography-ultraviolet method.
    Bouzas L; Hermida J; Tutor JC
    Ups J Med Sci; 2009; 114(1):55-61. PubMed ID: 19242874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between everolimus blood concentration assessed using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System sirolimus chemiluminescent microparticle immunoassay.
    Coentrão L; Carvalho C; Sampaio S; Oliveira JG; Pestana MI
    Transplant Proc; 2010 Jun; 42(5):1867-9. PubMed ID: 20620539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation.
    Baldelli S; Crippa A; Gabrieli R; Fiocchi R; Perico N; Merlini S; Ottomano C; Cattaneo D
    Clin Biochem; 2006 Dec; 39(12):1152-9. PubMed ID: 17054930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation.
    Khoschsorur G; Fruehwirth F; Zelzer S; Stettin M; Halwachs-Baumann G
    Clin Chim Acta; 2007 May; 380(1-2):217-21. PubMed ID: 17320846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients.
    Salm P; Warnholtz C; Boyd J; Arabshahi L; Marbach P; Taylor PJ
    Clin Biochem; 2006 Jul; 39(7):732-8. PubMed ID: 16725133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of sirolimus and everolimus measured by immunoassay techniques in whole blood samples from kidney transplant patients.
    Capone D; Gentile A; Polichetti G; Federico S; Sabbatini M; Acampora A; Basile V; Pieri M; Tarantino G
    Int J Immunopathol Pharmacol; 2008; 21(2):297-307. PubMed ID: 18547473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation.
    Moes DJ; Press RR; de Fijter JW; Guchelaar HJ; den Hartigh J
    Ther Drug Monit; 2010 Aug; 32(4):413-9. PubMed ID: 20535052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus.
    Strom T; Haschke M; Boyd J; Roberts M; Arabshahi L; Marbach P; Christians U
    Ther Drug Monit; 2007 Dec; 29(6):743-9. PubMed ID: 18043471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between a liquid chromatography-tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations.
    Dailly E; Deslandes G; Hourmant M; Petit T; Renaud C; Treilhaud M; Jolliet P
    J Clin Lab Anal; 2008; 22(4):282-5. PubMed ID: 18623123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of everolimus in blood samples from kidney and liver transplant recipients using the sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000® system.
    Hermida-Cadahia EF; Tutor JC
    Scand J Clin Lab Invest; 2012 Apr; 72(2):180-3. PubMed ID: 22248047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Larger dosage required for everolimus than sirolimus to maintain same blood concentration in two pancreatic islet transplant patients with tacrolimus.
    Sato E; Yano I; Shimomura M; Masuda S; Katsura T; Matsumoto S; Okitsu T; Iwanaga Y; Uemoto S; Inui K
    Drug Metab Pharmacokinet; 2009; 24(2):175-9. PubMed ID: 19430174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus.
    Wilson D; Johnston F; Holt D; Moreton M; Engelmayer J; Gaulier JM; Luthe H; Marquet P; Moscato D; Oellerich M; Mosso R; Streit F; Brunet M; Fillee C; Schmid R; Wallemacq P; Barnes G
    Clin Biochem; 2006 Apr; 39(4):378-86. PubMed ID: 16545357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Abbott ARCHITECT i2000 sirolimus assay and comparison with the Abbott IMx sirolimus assay and an established liquid chromatography-tandem mass spectrometry method.
    Johnson-Davis KL; De S; Jimenez E; McMillin GA; De BK
    Ther Drug Monit; 2011 Aug; 33(4):453-9. PubMed ID: 21743377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the reintroduced MEIA assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients.
    Morris RG; Salm P; Taylor PJ; Wicks FA; Theodossi A
    Ther Drug Monit; 2006 Apr; 28(2):164-8. PubMed ID: 16628125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoassay determination of rapamycin: reliability of the method with respect to liquid chromatography mass spectrometric quantification.
    Pieri M; Capone D; Gentile A; Miraglia N; Leo E; Federico S; Basile V; Acampora A
    Clin Transplant; 2007; 21(5):633-7. PubMed ID: 17845638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the CEDIA and MEIA assays for the measurement of sirolimus in organ transplant recipients.
    Colantonio DA; Borden KK; Clarke W
    Clin Biochem; 2007 Jun; 40(9-10):680-7. PubMed ID: 17428457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a new immunoassay to measure sirolimus blood concentrations compared to a tandem mass-spectrometric chromatographic analysis.
    Fillée C; Mourad M; Squifflet JP; Malaise J; Lerut J; Reding R; Borghgraef P; Vanbinst R; Wallemacq PE
    Transplant Proc; 2005; 37(6):2890-1. PubMed ID: 16182845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of QMS everolimus assay using Hitachi 917 Analyzer: comparison with liquid chromatography/mass spectrometry.
    Dasgupta A; Davis B; Chow L
    Ther Drug Monit; 2011 Apr; 33(2):149-54. PubMed ID: 21266941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.